Edition:
India

Reata Pharmaceuticals Inc (RETA.OQ)

RETA.OQ on NASDAQ Stock Exchange Global Market

156.20USD
7 Aug 2020
Change (% chg)

$4.30 (+2.83%)
Prev Close
$151.90
Open
$152.25
Day's High
$157.18
Day's Low
$151.16
Volume
93,392
Avg. Vol
121,291
52-wk High
$256.04
52-wk Low
$70.31

Latest Key Developments (Source: Significant Developments)

Reata Says Initiation Of Investigator-Sponsored Study Evaluating Bardoxolone For Complications Associated With COVID-19
Tuesday, 28 Jul 2020 

July 28 (Reuters) - Reata Pharmaceuticals Inc ::REATA ANNOUNCES INITIATION OF INVESTIGATOR-SPONSORED STUDY EVALUATING BARDOXOLONE FOR COMPLICATIONS ASSOCIATED WITH COVID-19.REATA PHARMACEUTICALS INC - AT NYU'S REQUEST, REATA IS PROVIDING DRUG SUPPLY FOR TRIAL.REATA PHARMACEUTICALS INC - NYU WILL BE INITIATING PHASE 2 BARCONA STUDY WITH A PRIMARY ENDPOINT OF SAFETY.  Full Article

Reata Pharmaceuticals Announces Receipt Of $350 Mln Related To Closing Of Previously Announced Strategic Investment
Thursday, 25 Jun 2020 

June 24 (Reuters) - Reata Pharmaceuticals Inc ::REATA PHARMACEUTICALS - ANNOUNCED RECEIPT OF $350 MILLION RELATED TO CLOSING OF PREVIOUSLY ANNOUNCED STRATEGIC INVESTMENT.REATA PHARMACEUTICALS - FINANCING INCLUDES $300 MILLION IN RETURN FOR SINGLE-DIGIT ROYALTY PAYMENTS ON WORLDWIDE NET SALES OF BARDOXOLONE METHYL.REATA PHARMACEUTICALS - FINANCING ALSO INCLUDES $50 MILLION INVESTMENT IN 340,793 SHARES OF CO'S CLASS A COMMON STOCK AT $146.72/SHARE.  Full Article

Reata Pharmaceuticals & Blackstone Life Sciences Announce $350 Million Strategic Investment
Thursday, 11 Jun 2020 

June 11 (Reuters) - Reata Pharmaceuticals Inc ::REATA PHARMACEUTICALS, INC. AND BLACKSTONE LIFE SCIENCES ANNOUNCE $350 MILLION STRATEGIC INVESTMENT.REATA PHARMACEUTICALS - FUNDS MANAGED BY BLACKSTONE LIFE SCIENCES WILL LEAD A $350 MILLION ROYALTY AND EQUITY INVESTMENT IN REATA.REATA PHARMACEUTICALS - INVESTMENT BY BLACKSTONE LIFE SCIENCES INCLUDES $300 MILLION IN RETURN FOR ROYALTY PAYMENTS ON WORLDWIDE NET SALES OF BARDOXOLONE.REATA PHARMACEUTICALS - FINANCING ALSO INCLUDES $50 MILLION INVESTMENT IN 340,793 SHARES OF REATA'S CLASS A COMMON STOCK AT $146.72 PER SHARE.  Full Article

Reata Pharmaceuticals Announces First Quarter 2020 Financial Results
Tuesday, 12 May 2020 

May 11 (Reuters) - Reata Pharmaceuticals Inc ::REATA PHARMACEUTICALS, INC. ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES AN UPDATE ON DEVELOPMENT PROGRAMS.Q1 NON-GAAP LOSS PER SHARE $0.89.Q1 GAAP LOSS PER SHARE $1.47.Q1 EARNINGS PER SHARE ESTIMATE $-1.98 -- REFINITIV IBES DATA.ON MARCH 31, 2020, WE HAD CASH AND CASH EQUIVALENTS OF $624.5 MILLION, AS COMPARED TO $664.3 MILLION AT DECEMBER 31, 2019.COLLABORATION REVENUE WAS $1.4 MILLION IN Q1 OF 2020, AS COMPARED TO $7.8 MILLION FOR SAME PERIOD OF YEAR PRIOR.EXPECTS EXISTING CASH AND CASH EQUIVALENTS TO BE SUFFICIENT TO ENABLE IT TO FUND OPERATIONS THROUGH END OF 2021.  Full Article

Reata Pharmaceuticals Reports Q4 Non-Gaap Loss Per Share $1.59
Thursday, 20 Feb 2020 

Feb 19 (Reuters) - Reata Pharmaceuticals Inc ::Q4 NON-GAAP LOSS PER SHARE $1.59.Q4 GAAP LOSS PER SHARE $5.91.Q4 REVENUE $2.7 MILLION.Q4 REVENUE ESTIMATE $6.9 MILLION -- REFINITIV IBES DATA.Q4 EARNINGS PER SHARE ESTIMATE $-3.90 -- REFINITIV IBES DATA.REATA PHARMACEUTICALS - BELIEVE EXISTING CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO ENABLE CO TO FUND OPERATIONS THROUGH END OF 2021.  Full Article

Reata Pharmaceuticals Inc Announces Pricing Of Upsized Class A Common Stock Public Offering
Thursday, 14 Nov 2019 

Nov 13 (Reuters) - Reata Pharmaceuticals Inc ::REATA PHARMACEUTICALS, INC. ANNOUNCES PRICING OF UPSIZED CLASS A COMMON STOCK PUBLIC OFFERING.REATA PHARMACEUTICALS - ANNOUNCED PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 2.4 MILLION SHARES AT A PRICE TO PUBLIC OF $183.00 PER SHARE.OFFERING WAS UPSIZED TO 2.4 MILLION SHARES FROM ORIGINAL OFFERING SIZE OF 2 MILLION SHARES.REATA PHARMACEUTICALS - GROSS PROCEEDS TO CO FROM OFFERING ARE EXPECTED TO BE $439.2 MILLION.  Full Article

Reata Pharmaceuticals Posts Q3 Loss Per Share Of $1.32
Tuesday, 12 Nov 2019 

Nov 12 (Reuters) - Reata Pharmaceuticals Inc ::REATA PHARMACEUTICALS, INC. ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS.Q3 EARNINGS PER SHARE ESTIMATE $-1.24 -- REFINITIV IBES DATA.Q3 LOSS PER SHARE $1.32.AT SEPTEMBER 30, HAD $240.1 MILLION IN CASH & CASH EQUIVALENTS.QTRLY TOTAL COLLABORATION REVENUE $8.24 MILLION VERSUS $5.17 MILLION.Q3 REVENUE VIEW $7.4 MILLION -- REFINITIV IBES DATA.  Full Article

Reata Announces Positive Topline Year One Results From Pivotal Phase 3 Cardinal Study Of Bardoxolone Methyl
Tuesday, 12 Nov 2019 

Nov 11 (Reuters) - Reata Pharmaceuticals Inc ::REATA ANNOUNCES POSITIVE TOPLINE YEAR ONE RESULTS FROM PIVOTAL PHASE 3 CARDINAL STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME.REATA PHARMACEUTICALS INC - ACHIEVED PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT IMPROVEMENT IN EGFR COMPARED TO PLACEBO AFTER 48 WEEKS OF TREATMENT.REATA PHARMACEUTICALS INC - ACHIEVED KEY SECONDARY ENDPOINT OF STATISTICALLY SIGNIFICANT IMPROVEMENT IN RETAINED EGFR COMPARED TO PLACEBO.REATA PHARMACEUTICALS INC - BARDOXOLONE WAS GENERALLY REPORTED TO BE WELL TOLERATED IN STUDY.  Full Article

Reata Pharmaceuticals Reacquires Rights From Abbvie To Develop And Commercialize Bardoxolone Methyl, Omaveloxolone, And All Next-Generation Nrf2 Activators
Thursday, 10 Oct 2019 

Oct 10 (Reuters) - Reata Pharmaceuticals Inc ::REATA PHARMACEUTICALS REACQUIRES RIGHTS FROM ABBVIE TO DEVELOP AND COMMERCIALIZE BARDOXOLONE METHYL, OMAVELOXOLONE, AND ALL NEXT-GENERATION NRF2 ACTIVATORS.REATA PHARMACEUTICALS INC - ABBVIE WILL RECEIVE A TOTAL OF $330 MILLION IN CASH, PRIMARILY FOR RIGHTS TO BARDOXOLONE.REATA PHARMACEUTICALS INC - REATA WILL MAKE AN UPFRONT PAYMENT OF $75 MILLION IN 2019.REATA PHARMA- ABBVIE WILL RECEIVE LOW SINGLE-DIGIT, TIERED ROYALTIES FROM WORLDWIDE SALES OF OMAVELOXOLONE AND CERTAIN NEXT-GENERATION NRF2 ACTIVATORS.REATA PHARMACEUTICALS - REATA HAS ALSO ENTERED INTO AN AMENDMENT TO ITS LOAN AND SECURITY AGREEMENT WITH OXFORD FINANCE LLC AND SILICON VALLEY BANK.REATA PHARMACEUTICALS INC - ABBVIE WILL NOT RECEIVE ROYALTIES ON BARDOXOLONE.REATA PHARMA - ACTIVELY PREPARING FOR COMMERCIAL LAUNCH OF BARDOXOLONE AND OMAVELOXOLONE IN U.S..REATA PHARMACEUTICALS INC - AMENDED AGREEMENT MAKES $75 MILLION AVAILABLE TO CO UPON POSITIVE, TOPLINE DATA FROM EITHER CARDINAL STUDY OR MOXIE STUDY.REATA PHARMACEUTICALS INC - OVERALL, TERM LOAN FACILITY INCREASED BY $30 MILLION, FROM $125 MILLION TO $155 MILLION.  Full Article

Reata Pharmaceuticals Reports Q1 Results
Thursday, 9 May 2019 

May 9 (Reuters) - Reata Pharmaceuticals Inc ::REATA PHARMACEUTICALS, INC. ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS.Q1 LOSS PER SHARE $0.98.Q1 EARNINGS PER SHARE ESTIMATE $-1.00 -- REFINITIV IBES DATA.FALCON PIVOTAL PHASE 3 TRIAL TO INITIATE IN MAY 2019.AT MARCH 31, 2019, CO HAD $313.1 MILLION IN CASH AND CASH EQUIVALENTS.  Full Article

BRIEF-Reata Pharmaceuticals Announces Receipt Of $350 Mln Related To Closing Of Previously Announced Strategic Investment

* REATA PHARMACEUTICALS - ANNOUNCED RECEIPT OF $350 MILLION RELATED TO CLOSING OF PREVIOUSLY ANNOUNCED STRATEGIC INVESTMENT